






Lineage	Variant	Time Appeared	Transmissibility	Severity of Disease	Break-thru Infections
	Ancestral	2019			
B1.1.7	Alpha	November, 2020			
	Beta	End of 2020	50% more than Alpha	More likely to result in hospitalization & mortality	
B.1.617.2	Delta	Late 2020	Twice as much as Beta	More severe in unvaccinated	Some
AY.4.2	Delta+		10-20% more than Delta		
BA.1, BA.1.1, BA.2, BA.3, BA.4 BA.5	Omicron	November, 2021	More than others		More
BQ.1, BQ.1.1,			More than BA strains		
BQ.1.1					
Othe	er: XBB (emerged fr	om prior BA variants),Gamma, E	psilon, Eta, lota, Kappa, Mu, .	Zeta, 1.617.3,	






































Post Covid Symptom	Persons most vulnerable	Timing	Cause	Treatment/Prevention
Weight Loss	All	During acute infection	Immune system cytokine production	Nutrition & Diet
Smell disruption	Younger female adults	Presenting symptom, or early post COVID period	Viral injury to	Retraining sense of sm
Depression	Younger adults Individuals with other medical problems	Up to one year post infection	Sleep disruption Immune system cytokine production Changes in gut microbiotome & neurotransmitter production	Exercise Meditation Discontinuation of alco Medical interventions
Autoimmune phenomenon	Symptomatic men; Asymptomatic women	Post infection	Antibody generation to normal cellular material	Maintenance of norma nutrition, sleep and ex

